PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF
Kuotasi per Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Penutupan Sebelumnya | 23.42 | Rentang Harian | 22.59 – 23.15 |
| Kisaran 52 Minggu | 7.06 – 24.15 | Volume | 23.96K |
| Volume Rata-Rata | 68.31K | AUM | $25.7M (Aug 27, 2026) |
| Expense Ratio | 1.22% | Yield (TTM) | 0.30% |
| NAV | 23.38 | Premium/Diskon | -2.35% indikatif |
| Inception | Nov 15, 2017 | Kepemilikan | 50 |
| Penerbit | Direxion | Bursa | AMEX |
| Kategori | Healthcare | Indeks yang Dilacak | Tidak tercantum dalam data sumber |
| CUSIP | 25460E646 | ISIN | US25460E6462 |
| Struktur | Berleverage 3x Invers | ||
| Manajemen | Tidak tercantum dalam data sumber | ||
Tentang ETF ini
PILL seeks to deliver investment results of 3x the daily performance of the S&P Pharmaceuticals Select Industry Index, a modified equal-weighted index that measures the performance of pharmaceutical companies, as defined by GICS, on the S&P Total Market Index. The fund uses derivatives and swaps to achieve its target exposure. As a levered product with daily resets, PILL is designed as a short-term trading tool and not a long-term investment vehicle. As a result, long-term returns could materially differ from those of the underlying index due to daily compounding. Prior to August 2, 2019, the fund aimed to provide 3x leveraged exposure to the Dynamic Pharmaceutical Intellidex Index. Effective February 27, 2026, the fund replaced the term Shares in its name with ETF.
Deskripsi dari penyedia data dana · profil per Aug 27, 2026.
Grafik Harga
Harga penutupan harian (imbal hasil harga, bukan imbal hasil total). Garis perbandingan dinormalisasi ke perubahan persentase dari awal rentang waktu. Sumber: Financial Modeling Prep.
Kinerja
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Return harga | +18.17% | +83.23% | +70.76% | +85.61% | +191.57% | +34.95% | +3.94% | — | -0.28% |
| Total return | +18.17% | +83.37% | +71.14% | +86.06% | +193.07% | +36.48% | +4.93% | — | +0.41% |
* Disetahunkan. Total imbal hasil menggunakan seri harga yang disesuaikan dengan dividen (distribusi diinvestasikan kembali); imbal hasil harga menggunakan harga penutupan tanpa penyesuaian. Kinerja hingga Aug 26, 2026. Kinerja masa lalu tidak menjamin hasil di masa depan.
Biaya
| Expense ratio bersih | 1.22% | Biaya tahunan untuk investasi $10.000 | $122.00 |
Hanya kalkulasi ilustrasi: expense ratio × $10.000. Tidak termasuk biaya perdagangan, selisih bid/ask, pajak, dan perubahan nilai investasi. Detail expense ratio bruto vs. neto dan setiap pengabaian biaya tersedia dalam prospektus.
Kepemilikan
Kepemilikan per Aug 22, 2026 — tanggal pelaporan portofolio dari penyedia data; kepemilikan bukan posisi langsung. 69 baris dalam basis data.
| # | Kepemilikan | Ticker | Bobot | Saham | Nilai Pasar |
|---|---|---|---|---|---|
| 1 | S&P PHARMACEUTICALS SELECT INDEX SWAP | — | 69.07% | 6.92K | $57.3M |
| 2 | GOLDMAN FINL SQ TRSRY INST 506 | — | 5.31% | 4.41M | $4.4M |
| 3 | DREYFUS GOVT CASH MAN INS | — | 3.23% | 2.68M | $2.7M |
| 4 | GOLDMAN SACHS FIN GOV 465 INSTITUT | — | 2.50% | 2.07M | $2.1M |
| 5 | AMYLYX PHARMACEUTICALS INC | AMLX | 0.83% | 17.45K | $692.1K |
| 6 | CRINETICS PHARMACEUTICALS IN | CRNX | 0.70% | 6.84K | $579.6K |
| 7 | MBX BIOSCIENCES INC | MBX | 0.61% | 7.58K | $502.9K |
| 8 | ATAIBECKLEY INC | ATAI | 0.56% | 62.14K | $461.1K |
| 9 | Definium Therapeutics, Inc | DFTX | 0.55% | 10.11K | $458.9K |
| 10 | OMEROS CORP | OMER | 0.52% | 23.03K | $429.0K |
| 11 | ENLIVEN THERAPEUTICS INC | ELVN | 0.45% | 6.35K | $374.0K |
| 12 | CORCEPT THERAPEUTICS INC | CORT | 0.44% | 3.01K | $364.0K |
| 13 | NUVATION BIO INC | NUVB | 0.42% | 51.29K | $350.3K |
| 14 | ETON PHARMACEUTICALS INC | ETON | 0.40% | 5.55K | $332.4K |
| 15 | TREVI THERAPEUTICS INC | TRVI | 0.39% | 17.53K | $319.9K |
| 16 | EDGEWISE THERAPEUTICS INC | EWTX | 0.37% | 7.14K | $309.0K |
| 17 | NEKTAR THERAPEUTICS | NKTR | 0.37% | 4.14K | $308.4K |
| 18 | OCULAR THERAPEUTIX INC | OCUL | 0.36% | 26.88K | $298.0K |
| 19 | MERCK & CO. INC. | MRK | 0.35% | 1.97K | $293.8K |
| 20 | PERRIGO CO PLC | PRGO | 0.35% | 21.03K | $288.1K |
| 21 | BRISTOL-MYERS SQUIBB CO | BMY | 0.33% | 4.23K | $276.7K |
| 22 | MAZE THERAPEUTICS INC | MAZE | 0.33% | 9.55K | $276.3K |
| 23 | HARROW INC | HROW | 0.33% | 6.54K | $275.2K |
| 24 | AMNEAL PHARMACEUTICALS INC | AMRX | 0.33% | 15.33K | $274.4K |
| 25 | TARSUS PHARMACEUTICALS INC | TARS | 0.33% | 3.83K | $273.9K |
| 26 | LIGAND PHARMACEUTICALS | LGND | 0.33% | 947 | $272.2K |
| 27 | ALUMIS INC | ALMS | 0.32% | 11.71K | $267.7K |
| 28 | VERADERMICS INC | MANE | 0.32% | 2.53K | $266.0K |
| 29 | JOHNSON & JOHNSON | JNJ | 0.32% | 985 | $263.4K |
| 30 | ROYALTY PHARMA PLC- CL A | RPRX | 0.31% | 4.31K | $261.0K |
| 31 | ELI LILLY & CO | LLY | 0.31% | 206 | $256.3K |
| 32 | LIQUIDIA CORP | LQDA | 0.31% | 3.60K | $255.8K |
| 33 | PFIZER INC | PFE | 0.31% | 9.18K | $255.0K |
| 34 | JAZZ PHARMACEUTICALS PLC | JAZZ | 0.31% | 1.02K | $254.4K |
| 35 | RAPPORT THERAPEUTICS INC | RAPP | 0.31% | 5.31K | $254.2K |
| 36 | HARMONY BIOSCIENCES HOLDINGS | HRMY | 0.30% | 6.62K | $252.0K |
| 37 | SUPERNUS PHARMACEUTICALS INC | SUPN | 0.30% | 5.21K | $247.2K |
| 38 | ELANCO ANIMAL HEALTH INC | ELAN | 0.29% | 10.27K | $242.0K |
| 39 | PRESTIGE CONSUMER HEALTHCARE | PBH | 0.29% | 4.78K | $241.5K |
| 40 | ORGANON & CO | OGN | 0.29% | 17.56K | $241.2K |
| 41 | VIATRIS INC | VTRS | 0.29% | 14.90K | $240.1K |
| 42 | PACIRA BIOSCIENCES INC | PCRX | 0.29% | 10.03K | $239.0K |
| 43 | ALTO NEUROSCIENCE INC | ANRO | 0.28% | 6.83K | $234.0K |
| 44 | INDIVIOR PHARMACEUTICALS INC | INDV | 0.28% | 6.17K | $233.0K |
| 45 | XERIS BIOPHARMA HOLDINGS INC | XERS | 0.28% | 27.07K | $232.8K |
| 46 | ANI PHARMACEUTICALS INC | ANIP | 0.27% | 2.87K | $221.9K |
| 47 | PHIBRO ANIMAL HEALTH CORP-A | PAHC | 0.27% | 6.29K | $221.4K |
| 48 | WAVE LIFE SCIENCES INC | WVE | 0.26% | 41.50K | $217.9K |
| 49 | ZOETIS INC | ZTS | 0.26% | 2.89K | $216.7K |
| 50 | INNOVIVA INC | INVA | 0.26% | 10.21K | $214.5K |
| 51 | ARVINAS INC | ARVN | 0.25% | 23.10K | $208.5K |
| 52 | AMPHASTAR PHARMACEUTICALS IN | AMPH | 0.25% | 9.54K | $206.9K |
| 53 | AXSOME THERAPEUTICS INC | AXSM | 0.24% | 953 | $198.3K |
| 54 | COLLEGIUM PHARMACEUTICAL INC | COLL | 0.22% | 6.75K | $185.9K |
| 55 | SEPTERNA INC | SEPN | 0.22% | 4.55K | $185.7K |
| 56 | LB PHARMACEUTICALS INC | LBRX | 0.22% | 3.78K | $178.5K |
| 57 | ACLARIS THERAPEUTICS INC | ACRS | 0.20% | 26.01K | $164.6K |
| 58 | CORMEDIX INC | CRMD | 0.20% | 19.75K | $162.6K |
| 59 | ZEVRA THERAPEUTICS INC | ZVRA | 0.19% | 13.27K | $157.8K |
| 60 | THERAVANCE BIOPHARMA INC | TBPH | 0.18% | 8.66K | $146.8K |
| 61 | PHATHOM PHARMACEUTICALS INC | PHAT | 0.16% | 15.08K | $129.7K |
| 62 | AQUESTIVE THERAPEUTICS INC | AQST | 0.15% | 28.30K | $127.2K |
| 63 | FULCRUM THERAPEUTICS INC | FULC | 0.13% | 29.02K | $111.7K |
| 64 | RELMADA THERAPEUTICS INC | RLMD | 0.13% | 23.54K | $109.2K |
| 65 | EYEPOINT INC | EYPT | 0.12% | 19.05K | $102.9K |
| 66 | EVOLUS INC | EOLS | 0.12% | 11.69K | $97.6K |
| 67 | BIOAGE LABS INC | BIOA | 0.11% | 9.42K | $91.3K |
| 68 | LEXICON PHARMACEUTICALS INC | LXRX | 0.11% | 40.31K | $87.9K |
| 69 | ESPERION THERAPEUTICS INC | — | 0.00% | 79.31K | $0.00 |
Klik ticker untuk melihat semua ETF yang memilikinya.
Eksposur Sektor
Eksposur Geografis
Bobot negara sebagaimana dilaporkan oleh penyedia data. Label pasar berkembang/maju/frontier mengikuti klasifikasi yang ada di halaman Metodologi. Lindung nilai mata uang: Tidak ada indikasi hedging pada nama dana.
Distribusi
| Yield (TTM) | 0.30% | Dibayarkan (12 bulan terakhir) | $0.0685 |
| Frekuensi | Quarterly | SEC yield | Tidak disediakan oleh sumber data kami — lihat halaman penerbit |
| Tanggal ex-dividen terakhir | Jun 23, 2026 | Pembayaran terakhir | $0.0152 (Jun 30, 2026) |
| Pertumbuhan 1T | -18.96% | Pertumbuhan 3T / 5T (tahunan) | -16.42% / — |
| Tanggal ex-dividen | Tanggal Pencatatan | Tanggal pembayaran | Jumlah |
|---|---|---|---|
| Jun 23, 2026 | Jun 23, 2026 | Jun 30, 2026 | $0.0152 |
| Mar 24, 2026 | Mar 24, 2026 | Mar 31, 2026 | $0.0109 |
| Dec 23, 2025 | Dec 23, 2025 | Dec 31, 2025 | $0.0326 |
| Sep 23, 2025 | Sep 23, 2025 | Sep 30, 2025 | $0.0098 |
| Jun 24, 2025 | Jun 24, 2025 | Jul 01, 2025 | $0.0245 |
| Mar 25, 2025 | Mar 25, 2025 | Apr 01, 2025 | $0.0183 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 31, 2024 | $0.0131 |
| Sep 24, 2024 | Sep 24, 2024 | Oct 01, 2024 | $0.0287 |
| Jun 25, 2024 | Jun 25, 2024 | Jul 02, 2024 | $0.0219 |
| Mar 19, 2024 | Mar 20, 2024 | Mar 26, 2024 | $0.0272 |
| Dec 21, 2023 | Dec 22, 2023 | Dec 29, 2023 | $0.0382 |
| Sep 19, 2023 | Sep 20, 2023 | Sep 26, 2023 | $0.0353 |
Yield distribusi trailing = total kas 12 bulan terakhir ÷ harga saat ini. Ini BUKAN yield 30 hari SEC dan distribusi tidak dijamin berlanjut. Penjelasan perbedaannya →
Statistik Risiko
| Volatilitas 1T / 3T | 65.24% / 59.96% | Sharpe 1T / 3T | 3.98 / 1.00 |
| Drawdown maks 1T / 3T | -33.21% / -60.45% | Sortino 1T | 6.33 |
| Beta vs S&P 500 (3T) | 2.15 | Korelasi vs S&P 500 (1T) | 0.356 |
| Deviasi sisi bawah 1 tahun | 40.93% | Tingkat bebas risiko yang digunakan | 3.71% (3M T-bill, FRED) |
Dihitung oleh ETF Explorer dari harga penutupan harian yang telah disesuaikan dividen; volatilitas dan drawdown merupakan angka yang disetahunkan/per periode; eksposur S&P 500 diproksikan oleh SPY. Per Aug 27, 2026. Rumus →
Likuiditas
| Volume hari ini | 23.96K | Volume rata-rata | 68.31K |
| AUM | $25.7M | Premium/Diskon | -2.35% |
| Spread bid/ask | Tidak disediakan oleh sumber data kami. Periksa layar kuotasi broker Anda; spread paling lebar pada saat pembukaan dan penutupan. | ||
Premium/discount membandingkan harga pasar tertunda dengan NAV yang terakhir dilaporkan — angka indikatif, bukan premium/discount penutupan resmi. Cara kerja likuiditas ETF →
Aliran Dana (estimasi)
| Periode | Est. arus bersih | % dari AUM awal | AUM awal → akhir |
|---|---|---|---|
| 1 Hari | $913.0K | +3.68% | $24.8M → $25.7M |
| 1 Minggu | $571.4K | +2.31% | $24.7M → $25.7M |
Estimasi ETF Explorer: perubahan AUM yang dilaporkan dikurangi dampak pergerakan pasar, dari snapshot harian kami. Bukan data kreasi/penebusan resmi penerbit.
Sumber Daya Resmi Dana
Tautan eksternal akan membuka situs penerbit atau SEC EDGAR di tab baru. Prospektus dan dokumen resmi selalu menjadi sumber yang berwenang — tinjau sebelum berinvestasi.
Berita Terkini untuk PILL
Tidak ada artikel yang menyebut dana ini secara langsung dalam 7 hari terakhir — menampilkan liputan ETF umum.
Panduan: AUM adalah ukuran dana. Expense ratio adalah biaya tahunan yang sudah tercermin dalam imbal hasil. NAV adalah nilai aset yang dimiliki dana per unit; harga pasar bisa sedikit di atas (premium) atau di bawah (diskon) NAV. Total return mengasumsikan distribusi diinvestasikan kembali. Setiap dataset menampilkan tanggal datanya masing-masing karena kepemilikan, aset, dan harga diperbarui pada jadwal yang berbeda.